Next Article in Journal
Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma
Next Article in Special Issue
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
Previous Article in Journal
Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-CSF1 Fusions
Previous Article in Special Issue
PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells
Open AccessReview

Acute Myeloid Leukemia: Aging and Epigenetics

1
Institute of Molecular Medicine, University of Ulm, 89081 Ulm, Germany
2
Center for Regenerative Medicine in Barcelona (CMRB), IDIBELL, Hospital Duran i Reynals, Av. Gran Via 199-203, 08908 Hospitalet de Llobregat, Barcelona, Spain
3
Institute of Molecular Medicine, University of Ulm, James-Franck-Ring 11c, 08090 Ulm, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 103; https://doi.org/10.3390/cancers12010103
Received: 14 November 2019 / Revised: 23 December 2019 / Accepted: 27 December 2019 / Published: 31 December 2019
(This article belongs to the Special Issue Acute Myeloid Leukemia)
Acute myeloid leukemia (AML) is an aggressive hematological disorder mainly affecting people of older age. AML initiation is primarily attributed to mutations in crucial cellular regulators such as epigenetic factors, transcription factors, and signaling genes. AML’s aggressiveness and responsiveness to treatment depends on the specific cell type where leukemia first arose. Aged hematopoietic cells are often genetically and/or epigenetically altered and, therefore, present with a completely different cellular context for AML development compared to young cells. In this review, we summarize key aspects of AML development, and we focus, in particular, on the contribution of cellular aging to leukemogenesis and on current treatment options for elderly AML patients. Hematological disorders and leukemia grow exponentially with age. So far, with conventional induction therapy, many elderly patients experience a very poor overall survival rate requiring substantial social and medical costs during the relatively few remaining months of life. The global population’s age is increasing rapidly without an acceptable equal growth in therapeutic management of AML in the elderly; this is in sharp contrast to the increase in successful therapies for leukemia in younger patients. Therefore, a focus on the understanding of the biology of aging in the hematopoietic system, the development of appropriate research models, and new therapeutic approaches are urged. View Full-Text
Keywords: acute myeloid leukemia (AML); aging; epigenetic; hematopoietic stem cell (HSC); clonal hematopoiesis (CH); mutation acute myeloid leukemia (AML); aging; epigenetic; hematopoietic stem cell (HSC); clonal hematopoiesis (CH); mutation
Show Figures

Figure 1

MDPI and ACS Style

Zjablovskaja, P.; Florian, M.C. Acute Myeloid Leukemia: Aging and Epigenetics. Cancers 2020, 12, 103.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop